Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

Authors:

Abstract
No abstract available
Funding Information
  • Ottawa Hospital Foundation
  • American Society of Clinical Oncology (OCREB 1-866-678-6427 Ext 6649)
  • Canadian Institutes of Health Research

This publication has 26 references indexed in Scilit: